Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Lenvatinib (E7080) - ≥99%, high purity , CAS No.417716-92-8, Inhibitor of fms related receptor tyrosine kinase 4;Inhibitor of kinase insert domain receptor

  • Moligand™
  • ≥99%
Item Number
L125518
Grouped product items
SKUSizeAvailabilityPrice Qty
L125518-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$48.90
L125518-10mg
10mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$68.90
L125518-50mg
50mg
In stock
$147.90
L125518-250mg
250mg
In stock
$506.90
L125518-1g
1g
In stock
$1,822.90
L125518-5g
5g
In stock
$8,201.90
Add to Wish List Compare
Bulk Order  SDS  DATASHEET
View related series
fms related receptor tyrosine kinase 4 Inhibitor kinase insert domain receptor Inhibitor

Basic Description

SynonymsLenvatinib|417716-92-8|E7080|4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide|E7080 (Lenvatinib)|Lenvatinib (E7080)|E-7080|ER-203492-00|E 7080|Lenvatinib free base|Kisplyx|UNII-EE083865G2|4-{3-Chloro-4-[(Cyclopropylcarbamoyl)am
Specifications & PurityMoligand™, ≥99%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of fms related receptor tyrosine kinase 4;Inhibitor of kinase insert domain receptor
Note5mg、10mg、100mg卖完停产，不再备货
Product Description

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. Phase 3.

Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.

Names and Identifiers

Pubchem Sid488196334
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488196334
IUPAC Name 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
INCHI InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
InChi Key WOSKHXYHFSIKNG-UHFFFAOYSA-N
Canonical SMILES COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
Isomeric SMILES COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
Alternate CAS 417716-92-8
PubChem CID 9823820
MeSH Entry Terms 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide;4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide;4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxami
Molecular Weight 426.85

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

16 results found

Lot NumberCertificate TypeDateItem
D2219078Certificate of AnalysisFeb 21, 2024 L125518
H2127404Certificate of AnalysisJun 08, 2023 L125518
H2127405Certificate of AnalysisJun 08, 2023 L125518
H2127406Certificate of AnalysisJun 08, 2023 L125518
H2127407Certificate of AnalysisJun 08, 2023 L125518
C2127090Certificate of AnalysisJan 12, 2023 L125518
B23081009Certificate of AnalysisNov 17, 2022 L125518
B2308857Certificate of AnalysisNov 17, 2022 L125518
B2308858Certificate of AnalysisNov 17, 2022 L125518
B2308865Certificate of AnalysisNov 17, 2022 L125518
B2308866Certificate of AnalysisNov 17, 2022 L125518
B2308918Certificate of AnalysisNov 17, 2022 L125518
B2308919Certificate of AnalysisNov 17, 2022 L125518
H1623002Certificate of AnalysisMay 09, 2022 L125518
D2219077Certificate of AnalysisMar 05, 2022 L125518
D2219090Certificate of AnalysisMar 05, 2022 L125518

more

Chemical and Physical Properties

SolubilityDMSO 40 mg/mL (93.7 mM); Water <1 mg/mL (<1 mM); Ethanol <1 mg/mL (<1 mM)

Related Documents

 SDS

 Specification Sheet

References

1. Musumeci F, Radi M, Brullo C, Schenone S.  (2012)  Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors..  J Med Chem,  55  (24): (10797-822).  [PMID:23098265]
2. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J et al..  (2018)  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial..  Lancet,  391  (10126): (1163-1173).  [PMID:29433850]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.